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CObjectives: Considering rising health expenditure on the one hand
and increasing public expectations on the other hand, there is a need
for explicit health care rationing to secure public acceptance of cover-
age decisions of health interventions. The National Health Security
Office, the institute managing the Universal Coverage Scheme in Thai-
land, recently called for more rational, transparent, and fair decisions
on the public reimbursement of health interventions. This article de-
scribes the application of multicriteria decision analysis (MCDA) to
guide the coverage decisions on including health interventions in the
Universal Coverage Scheme health benefit package in the period
2009–2010.Methods: We described the MCDA priority-setting process
hrough participatory observation and evaluated the rational, trans-
arency, and fairness of the priority-setting process against the ac-
ountability for reasonableness framework. Results: The MCDA was
pplied in four steps: 1) 17 interventions were nominated for assess-
ent; 2) nine interventions were selected for further quantitative as- O
ntion
al So
http://dx.doi.org/10.1016/j.jval.2012.06.006essment on the basis of the following criteria: size of population af-
ected by disease, severity of disease, effectiveness of health
ntervention, variation in practice, economic impact on household ex-
enditure, and equity and social implications; 3) these interventions
ere then assessed in terms of cost-effectiveness and budget impact;
nd 4) decision makers qualitatively appraised, deliberated, and
eached consensus on which interventions should be adopted in the
ackage. Conclusion: This project was carried out in a real-world con-
ext and has considerably contributed to the rational, transparent, and
air priority-setting process through the application of MCDA. Al-
hough the present project has applied MCDA in the Thai context,
CDA is adaptable to other settings.
eywords: multicriteria decision analysis, priority setting, UC benefit
ackage.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
High-cost health interventions including pharmaceuticals and
medical technologies are increasingly becoming available in Thai-
land, increasing public and patient expectations. Because of lim-
ited resources, however, the government cannot make all these
interventions available to the population and this makes the need
for priority setting of interventions more and more explicit. In the
past, decisions on the public reimbursement of interventionswere
typically ad hoc and not transparent [1,2]: for example, certain
interest groups (such as politicians, health professionals, or indus-
try) could selectively advocate new interventions for public reim-
bursement. The decision-making processes often lack a system-
atic way without clear criteria for making coverage decisions.
Decision makers in Thailand have recently acknowledged this in-
adequate process and called for more rational, transparent, and
fair decisions on the public reimbursement of interventions to
improve population health in the country [3]. As a spring-off, the
National Health Security Office (NHSO), the institute thatmanages
the largest health plan in Thailand (Universal Coverage Scheme
[UC]), initiated a collaborative research and development project
* Address correspondence to: Sitaporn Youngkong, Health Interve
Tiwanon Road, Muang, Nonthaburi 11000, Thailand.
E-mail: sitaporn.y@hitap.net, S.Youngkong@elg.umcn.nl.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.with two independent research institutes—the Health Interven-
tion and Technology Assessment Program and the International
Health Policy Program—in 2009. The aim of the project was to
develop an optimal strategy for the development of the UC benefit
package, that is, to determine which interventions should be can-
didate for public reimbursement.
At the outset of the project, it was decided to use multicriteria
decision analysis (MCDA) as an overall methodological approach
for its potential for rational and transparent priority setting [4,5].
MCDA is defined as “a set of methods and approaches to aid deci-
sion-making, where decisions are based on more than one crite-
rion, whichmake explicit the impact of all the criteria applied and
the relative importance attached to them” [5].
This article describes the application of MCDA to support the
coverage decisions on including health interventions in the Thai
UC health benefit package in the period 2009–2010. We addressed
the following research question: “Does the use of MCDA lead to
(more) rational, transparent, and fair decisions in the develop-
ment of the UC benefit package in Thailand?” In the absence of a
clear standard on all aspects, we evaluated the present project
against the accountability for reasonableness (A4R) framework
and Technology Assessment Program, Ministry of Public Health,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
962 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 6 1 – 9 7 0[6,7], which specifies conditions for fair decision making. In doing
so, the framework also considers the aspects of rational and trans-
parent priority setting.
To our knowledge, this is the first time in a low- or middle-
income country that MCDA is practically used including a deliber-
ative process andmultiple stakeholders’ involvement to guide na-
tional-level priority setting in health care coverage decisions. The
experience of Thailand, and therefore this article, also holds rele-
vance for other countries, as it may inform them on the options
and limitations of MCDA for setting priorities in health.
Multicriteria decision analysis
Empirical evidence suggests that a number of criteria including
efficiency, equity (e.g., giving priority to the severely ill or the
poor), financial protection, and political considerations are consid-
ered important by policymakerswhen setting priorities [8–10]. It is
far from easy for policymakers, however, to consider these criteria
simultaneously—evidence on all criteria is not always available,
criteria are not equally important andmay even conflict with each
other, and policymakers (as people in general) are not good at
absorbing dissimilar types of information—and risk cognitive
overload [4]. This has prompted the use of MCDA for priority set-
ting (Fig. 1) [4]. MCDA allows the identification of a comprehensive
set of criteria, establishes the performance of interventions on
those criteria in a so-called performancematrix, and then inspects
the performance matrix qualitatively or quantitatively to rank or-
der interventions [4]. In a qualitative inspection, policymakers
simply interpret the performance matrix and make implicit judg-
ments on the weights of the various criteria. In a quantitative
inspection, policymakers weigh the different criteria on the basis
of their relative importance, and multiply the scores by the
weights to obtainweighed averages for all interventions. Interven-
tions can subsequently be rank ordered according to these
weighed averages.Fig. 1 – Ad hoc priority setting and rational priorMethods
We described the MCDA priority-setting process through partici-
patory observation. We evaluated the rational, transparency, and
fairness of the priority-setting process against the A4Rframework
[6,7]. The framework specifies the four conditions for fair decision
making. In doing so, the framework also considers the aspects of
rational and transparent priority setting.
The whole process involved a project team (including NHSO,
the Health Intervention and Technology Assessment Program,
and the International Health Policy Program) and a research team
(including the Health Intervention and Technology Assessment
Program and the International Health Policy Program). At the be-
ginning of the project, the research team reviewed the interna-
tional experience on the development of public health benefit
packages to further refine and operationalize the methodological
approach. The review documented the experience of seven health
technology assessment organizations in Canada, England and
Wales, the United States, the Netherlands, Germany, Sweden, and
Spain, which all use an explicit process of priority setting (Table 1).
The review concluded that all these organizations consider mul-
tiple criteria, involve multiple stakeholders, and distinguish, in
one way or another, four basic steps in their priority-setting pro-
cess. These steps were then also applied in the Thai setting and
included 1) nomination of interventions for assessment, 2) selec-
tion of interventions for assessment, 3) technology assessment of
interventions, and 4) appraisal of interventions.
For steps 1 and 2, the project team established a consultation
panel (panel 1) to reach consensus on who should be involved in
these steps and which criteria should be included as the selec-
tion criteria. Participants of the consultations were identified by
their expertise and selected purposively to cover stakeholders
who play an important role in the Thai health insurance system.
The four steps are discussed in detail in the following subsec-
tions.ity setting. From Baltussen and Niessen [4].
963V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 6 1 – 9 7 0Step 1: Nomination of interventions for assessment
The consultation panel 1 reached consensus to include a large
variety of stakeholders in step 1, reasoning that coverage deci-
sions also have broad consequences for the population of Thai-
land. Consequently, the NHSO established a working group in-
Table 1 – The results of the reviews regarding stakeholder
NICE CADT
Stakeholder involvement in nomination step
Policymakers ● ●
Health professionals ● ●
Academics ● ●
Patients ● ●
Civil society ●
Private sector ●
General populations ●
International organizations
Organizational employees ● ●
Stakeholder involvement in selection step
Policymakers ● ●
Health professionals ● ●
Academics ● ●
Patients ●
Civil society ●
Private sector
General populations ● ●
International organizations
Organizational employees ● ●
Criteria used in selection of health technology
assessment topics
Variation ● ●
Resource impact ●
Necessity
Effectiveness ●
Efficiency
Cost of intervention
Individual responsibility
Translating new knowledge into clinical
practice or care
Possibility of change in cost
Burden/severity of disease ●
Need for knowledge of the problem
Urgency/timeliness ●
Number of potential patients ●
Policy importance ●
Equity/ethical and social implication ● ●
Economic impact ● ●
Sufficient evidence for assessment
Criteria used in health intervention assessment
Effectiveness/efficacy ● ●
Safety
Cost ●
Cost-effectiveness ● ●
Budget impact ●
Population impact ●
Planning/utilization/legal issues ●
Equity/ethical and social implication ●
CADTH, Canadian Agency for Drug and Technologies in Health (Can
DAHTH, German Agency for Health Technology Assessment (German
and Wales); NL, Netherlands; SBU, Swedish Council on Technology
Technology Assessment Program (the United States).cluding representatives of seven groups— policymakers (i.e.,decision makers at the Ministry of Public Health and other three
public health insurance schemes); health professionals (i.e., rep-
resentatives from health professional associations); academics, pa-
tients, and civil society (i.e., representatives from nongovernment
organizations that are managed as permanent associations with le-
lvement and criteria used.
The reviewed organizations
VATAP Health Council
of the NL
SBU DAHTH CAHTH
● ● ●
● ● ● ●
● ● ● ●
● ● ●
●
● ●
●
●
● ●
● ●
● ● ● ●
● ● ●
●
●
●
●
● ● ● ●
●
● ● ● ●
● ●
● ● ●
●
● ● ●
●
● ● ●
●
● ● ●
● ● ●
● ●
● ●
● ● ● ● ●
●
● ● ● ●
●
●
● ●
CAHTH, Catalan Agency for Health Technology Assessment (Spain);
CE, the National Institute for Health and Clinical Excellence (England
ssment in Health Care (Sweden); VATAP, Veteran Administration’sinvo
H
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y); NI
Assegal status); industry (i.e., representatives from multiinternational
●●
●
●
t
a
m
t
s
t
e
i
p
a
i
t
m
A
i
w
i
n
t
p
m
c
h
M
d
964 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 6 1 – 9 7 0and local pharmaceutical companies, and medical devices indus-
tries); and laypeople (i.e., citizen constituencies of the Thai National
Health Assembly)—but excluded international organizations and
the researcherswho conduct health technology assessment because
their interests may not reflect that of society. The representatives of
these different stakeholder groups were nominated by their own
groups. Eachworking groupmemberwas then assigned to propose a
maximum of three interventions, including supportive information
of the performance of these interventions on the established criteria.
A total of 17 interventions were nominated.
Step 2: Selection of interventions for assessment
As to the selection criteria, the research team—through its re-
view—identified a range of criteria that are being used interna-
tionally (Table 1). The research team made sure that all criteria
were sound and relevant to the Thai context. This list of criteria
was put forward to consultation panel 1 as an input for discussion.
The panel initially agreed with considering the criteria that were
frequently used in the health technology assessment organiza-
tions. On consultationwith panel 1, consensuswas reached on the
use of six criteria: 1) size of population affected by the disease, 2)
severity of disease, 3) effectiveness of health intervention, 4) vari-
ation in practice, 5) economic impact on household expenditure,
and 6) equity/ethical and social implications. Subsequently, the
research team worked with a second consultation panel (panel 2)
including policymakers and academics to further develop these
criteria (i.e., establishing their definitions andmeasurement). The
panel agreed to score the performance of each intervention on
each criterion on an ordinal scale from 1 to 5. The panel decided to
give all criteria equal weight and that this could be changed in the
future when necessary. The results of the panel discussions are
presented in Table 2. The criteria are discussed in turn below.
● Size of population affected by disease. The size of the population
affected by the disease holds a positive relationship with the
impact of that disease for society and is therefore an important
criterion for priority setting, the panel argued. As indicator, the
panel agreed to use the prevalence of the disease and scaled
the prevalence on various levels.
● Severity of disease. Thai society generally gives high priority to
interventions that target the severely ill because of their
greater need for health care [11]. The panel defined the severity
of disease on the basis of health state valuations, with a range
from 0 (worst health status) to 1 (best health status), and de-
fined five levels. Following a Thai study that showed that some
people considered some health states worse than death [12],
the panel agreed that the lowest scale could be less than 0.
Effectiveness of health interventions. Effectiveness relates to the
outcomes of interventions and is a routinely used criterion in
priority setting [13,14]. Effectiveness is often expressed in qual-
ity-adjusted life-years (QALYs), but the panel did not consider
this suitable for this step because the effectiveness of interven-
tions in terms of QALYs was not available for all interventions
and could not be made available within the limited study pe-
riod. Therefore, the panel created a separate scoring system for
three categories of interventions: treatment/rehabilitation
(giving higher priority to interventions that cure a disease than
only improve quality of life), screening/diagnostic (giving
higher priority to interventions with high accuracy [60%] tar-
geting a curable disease), and preventive (giving higher priority
to interventions that can prevent 60% of a disease).
Variation in practice. All Thai citizens are covered by a public
health plan (the Civil Servant Medical Benefit Scheme for civil
servants, state enterprise employees, and their dependents;
the Social Security Scheme for private sector employees; and
the UC for the rest of the population). Because these plans hold
different agreements with health providers, there is growingconcern about the inequity in health services delivered to ben-
eficiaries of the different plans [15]. The panel acknowledged
the differences in intervention coverage between the health
plans, and across the country, and therefore the importance of
this criterion. The panel developed different scales to reflect
variation in practice, taking into account the source of evidence
(local, national, or international).
Economic impact of household expenditure. One of the objectives of
the UC is to protect household income from catastrophic
health expenditure [16,17]. The literature defines catastrophic
expenditure as households’ spending on direct health care costs
(e.g., medicines) that exceeds 10% of households’ expenditure
[15,18,19]. The panel adopted this definition to establish the
scoring scale of this criterion. The scale was established by
dividing the 10% top rank of the average household expendi-
ture on health care (baht per year) from a national household
socioeconomic survey conducted in 2008 [20] into quintile
groups and then using the upper value of each expenditure
interval for setting the scores.
Equity/ethical and social implication. The panel considered ethical
and social implications of interventions to be important and
argued that the poor and patients with rare diseases are— in a
moral sense—more deserving of health care than are others.
The panel decided that priority should be given to diseases that
are more frequent among the poor (based on World Health
Report 2002 that classifies poverty as a risk factor of disease)
[21]. In the absence of adequate definitions of “rare diseases” in
Thailand, the panel decided to use the lowest prevalence level
of the criterion “size of population affected by disease” (preva-
lence  10,000) as a threshold.
As to the selection of interventions for assessment, the consul-
ation panel (panel 1) determined to use the same working group
s mentioned above but without the representatives of policy-
akers and industry (because they were considered to have a po-
ential conflict of interest) and laypeople (because they were con-
idered difficult to identify, and to be adequately represented by
he representatives from civil society), and thisworking groupwas
stablished by theNHSO. The research team reviewed the 17 nom-
nated interventions against the six selection criteria and then
resented all information to theworking group. Because of limited
nd incomparable information on severity of disease for the nom-
nated interventions, the working group decided to omit this cri-
erion. The performances of the 17 interventions on the five re-
aining criteria were summarized in a performance matrix (see
ppendix 1). On inspection and deliberation, they selected nine
nterventions for further assessment. Of these interventions, eight
ere selected because they scored best in the overall ranking. One
ntervention “absorbent products for urinary and fecal inconti-
ence among disabled and elderly people” was added because the
arget group was considered to be vulnerable and deserving of
ublicly funded health care. NHSO’s Subcommittee for Develop-
ent of Benefit Package and Service Delivery (SCBP), which in-
ludes multidisciplinary stakeholders, that is, policymakers,
ealth professionals, civil society, and patient groups, approved in
ay 2010 that these nine interventions would be the subject of
etailed assessment.
Step 3: Technology assessment of interventions
The research team proposed another set of criteria (assessment
criteria) for detailed assessment of the nine interventions. In addi-
tion to the review results from the international literature (Table
1), the research team put forward results of a recent study on the
criteria and its weight (elicited by discrete choice experiments) for
priority setting, as conducted in Thailand [22]. This study sug-
gested the following criteria to be important: type of intervention
(classified by the objective of intervention, i.e., prevention or treat-
965V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 6 1 – 9 7 0Table 2 – Selection criteria.
Criteria Definition Parameter Scoring
1. Size of population
affected by disease
Number of people affected by the disease or
health problem that is treated or
prevented by the proposed intervention
among Thai population at a specified
time
Prevalence 5  500,000
4  100,001–500,000
3  50,001–100,000
2  10,001–50,000
1  10,000
2. Severity of disease Severity of disease or health problem that is
treated or prevented by the proposed
intervention by considering its impact on
the patients’ QOL
QOL score 5  0.60
4  0.41–0.60
3  0.21–0.40
2  0.01–0.20
1  0
3. Effectiveness of health
intervention
The final outcomes of the proposed
intervention that benefit the patients
with regard to the objective of the
intervention
3.1 For treatment/rehabilitation:
Capacity of the proposed intervention to
treat or rehabilitate the patients from the
disease and its impact on the patients’
QOL
The clinical benefit of the
proposed intervention and
improvement in QOL
5  cure
4  prolong life and major
improvement in QOL
3  prolong life and minor
improvement in QOL
2 major improvement in QOL
1 minor improvement in QOL
3.2 For screening/diagnostic:
Quality of the proposed intervention to
screen or diagnose the disease of the
patients and the expected outcome
beyond the screening or diagnostic
Accuracy of the intervention
and whether the screened
disease could be cured
5  accuracy 80% and screened
disease could be cured
4  accuracy 60%–80% and screened
disease could be cured
3  accuracy 80% but screened
disease could not be cured
2  accuracy 60%–80% and screened
disease could not be cured or
accuracy 60% and screened
disease could be cured
1  accuracy 60% and screened
disease could be cured
3.3 For prevention:
Risk reduction or preventive capacity
provided by the proposed intervention to
the population
Effectiveness of the
intervention to prevent the
disease
5  90%
4  81%–90%
3  71%–80%
2  61%–70%
1  60%
4. Variation in practice Variation of implementing the intervention
in practice that leads to unequal
accessibility to the intervention among
Thais. Variation in practice could be
identified from the different coverage of
the three publicly funded health
insurance schemes in Thailand and/or
could be identified from the different
distribution of the intervention
throughout the country
The difference of the benefit
packages between the three
health insurance schemes in
Thailand
The difference of health
interventions distribution
5  national evidence presenting
variation in practice in Thailand
4  national evidence presenting
variation in practice in some areas
3  international evidence
presenting variation in practice in
other countries that could assume
there is variation in practice in
Thailand
2  no evidence but we could
assume there is variation in
practice in Thailand
1  no variation in practice
5. Economic impact on
household expenditure
Impact on household expenditure as a
consequence of providing health
intervention to a family member with
consideration of catastrophic illness or
health catastrophe
Direct medical and nonmedical
household expenditure as a
consequence of the disease
or health problem per year
5  62,500 baht/y
4  35,601–62,500 baht/y
3  20,801–35,600 baht/y
2  12,000–20,800 baht/y
1  12,000 baht/y
6. Equity/ethical and
social implication
Priorities for specific groups of patients, i.e.,
the poor with rare disease, reflect the
moral values that should be considered
by policymakers
Disease of the poor
Prevalence 1,000 (rare
disease)
5  targeting the poor and
prevalence 1,000
4  targeting the poor and
prevalence 1,000–10,000
3  targeting the poor and
prevalence 10,000
2  not targeting the poor and
prevalence 1,000 or not targeting
the poor and prevalence
1,000–10,000
1  not targeting the poor and
prevalence 10,000QOL, quality of life.
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966 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 6 1 – 9 7 0ment), target group of intervention (classified by age group), sever-
ity of disease, number of beneficiaries, value for money, and bud-
get impact. The research team considered all criteria and argued
that—because the assessment criteria in the present step fol-
low-up on the selection criteria used in step 2—overlap should be
avoided. On careful assessment of all criteria and deliberation, the
research team came to the consensus to use two assessment cri-
teria: “value for money” and “budget impact.” Because of the nu-
merical nature of these two criteria, the research team decided
they were not further scaled.
● Value for money. The criterion value formoney refers to themax-
imization of health outcomes given a certain budget and is an
often-cited criterion for priority setting [13,14,23]. The research
teamdefined the criterion in terms of incremental cost per QALY
(so-called incremental cost-effectiveness ratio [ICER]) to allow
comparison across a broad range of interventions.
● Budget impact. The research team considered affordability of
inclusion of an intervention in the UC benefit package to be
important. This criterion addresses the budget impact by esti-
mating the financial consequences of adoption and diffusion of
a new intervention within a specific setting, while considering
the fiscal capacities of the health plan [24,25].
The SCBP then approved these two criteria to be used in the
assessment. Subsequently, the research team assessed the nine
interventions in terms of their value for money (ICER) and budget
impact (Table 3) and collaborated with external experts and rele-
vant stakeholders for each intervention for that purpose. The
ICERswere calculated by quantifyingmarginal costs and QALYs of
new interventions versus standard practice following health eco-
nomic evaluation guidelines in Thailand [27] and were therefore
reliable and comparable.
In addition, the SCBP requested information of the perfor-
mance of all nine interventions on the selection criteria (as dis-
cussed above)—these were also considered in the appraisal of the
interventions.
Step 4: Appraisal of interventions
In the fourth step, in July-August 2010, the research team pre-
sented the results of the assessment of nine interventions to the
SCBP for appraisal, that is, for final decision on inclusion of inter-
ventions in the benefit package (Table 3). The SCBPmembers elab-
orated on these assessments, and discussions focused on three
major issues: which costs were included in the models, whether
the most cost-effective alternative intervention of each disease
was already covered in the benefit package, and whether the pro-
posed intervention would be feasible for implementation. They
considered a threshold of one time gross domestic product per
capita (approximately US $4500 in 2010 [28]) per QALY gained as
good value formoney. Table 4 shows the relationship between the
results of step 3 (technology assessment) and those of step 4 (ap-
praisal). Two of the nine interventions were analyzed in terms of
costs only (one of themwas recommended by the SCBP), and their
results are also not included in Table 4. Of the other seven inter-
entions, the SCBP agreed to recommend three interventions for
urther consideration to be adopted under the UC scheme (Table 4)
ecause they were cost-effective with low budgetary impact. At
he same time, for two of these three interventions, it was found
hat cost-effective alternatives were already covered under the
enefit package (i.e., lamivudine for treating people with chronic
epatitis B and intravenous cyclophosphamide azathioprine for
reating severe lupus nephritis).
The other four interventions were not selected for a number of
easons. Some interventions (i.e., treatment for people with
hronic hepatitis C and absorbent products for urinary and fecal
ncontinence among disabled and elderly people) were cost-effec- tive, but the budgetary impact of the intervention was considered
oo high. One intervention “anti-immunoglobulin E for severe
sthma” was not cost-effective with high budgetary impact. Fi-
ally, the intervention “implant dentures for people who have
roblems with conventional complete dentures” was cost-effec-
ive but the SCBP denied to appraise it because there had been
oor service accessibility to current alternatives that would first
eed to be solved. No intervention yielding an ICER of higher than
ne time gross domestic product per capita per QALY gained was
ecommended for the benefit package.
Whether this use ofMCDA indeed improved rational, transpar-
ncy, and fairness of the priority-setting process in Thailand is not
asy to judge in the absence of a clear standard on all these as-
ects. As an alternative, we evaluated the project against the A4R
ramework [6,7], which specifies conditions for fair decision mak-
ng: reasonableness, publicity, revisable, and enforcement. In do-
ng so, the framework considers aspects of rational and transpar-
ncy at the same time.
The reasonableness condition states that the rationale for priori-
y-setting decisions must rest on evidence and principles that are
ccepted as relevant by fair-minded people. In the present project,
ontributing elements in this were the following: both selection
nd assessment criteria were identified and approved by a large
ariety of stakeholders (including consultation panel 1, the re-
earch team, and the SCBP) on the basis of literature review and
areful elaboration and supported by a previous study on priority-
etting criteria in Thailand [22]. In addition, the definition and
cales of the criteria were adapted to the Thai context, and the
erformance of interventions on every criterion was supported by
vailable local evidence. Also, the nomination, selection for as-
essment, and final priority setting was based on elaboration
mong a wide variety of stakeholders in working groups— the
atter is described as a key aspect of fair processes [29]. Limiting
lements were that the project did observe some difficulties in the
orking groups as to identifying true representatives of various
takeholders, for example, that of laypeople. Also, while the proj-
ct involved a range of stakeholders in its consultation panels and
orking groups in steps 1 to 3, the SCBP eventuallymade decisions
tself and it is not sure towhat extent the final decisions still reflect
he stakeholders’ preferences.
The publicity condition prescribes that rationales for priority-
etting decisions must be publicly accessible. The present project
ommunicated information on criteria and the selection of inter-
entions for assessment to stakeholders and the general public
hrough a newsletter, chapters in the newspaper, formal letters,
nd organizational Web sites. However, the reasons underlying
he final decisions regarding the adoption of interventions in the
ackage were not explicitly acknowledged. As a result, the work-
ng groups had requested the SCBP to provide them an official
etter explaining why particular interventions were included or
xcluded in the benefit package, and subsequently, the SCBP re-
uctantly accepted it. Although this is a way of sharing the mes-
age with the public, there is a need for an assessment of the
ffectiveness of this mode of communication in the future. The
evisable condition allows for challenging the decisions and giving
pportunities for revision and improvement of policies in the light
f new evidence. Yet, the present project did not have a systematic
ppealmechanism to challenge the coverage decisions. Neverthe-
ess, the process information and the criteria involved in the orig-
nal decision are publicly accessible and allow the general public to
xpress its dissatisfaction. This can lead to reconsidering the de-
isions in light of new evidence and better arguments. The enforce-
ent condition can be either voluntary or regulation of the process
o ensure that the first three above-mentioned conditions aremet.
ased on the 1-year experience, there was no rule and regulation
o reach this condition.
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Health interventions Results Policy recommendations
Cost-utility analysis* Budget impact analysis*
1. Treatment for people with
chronic hepatitis B
Lamivudine (produced by GPO) is the
most cost-effective (cost-saving)
compared with palliative care and with
the other alternatives:
- Lamivudine (original),
- Adefovir  lamivudine (GPO),
- Entecavir,
- Telbivudine, and
- Pegylated interferon alpha
The budget of providing lamivudine
(GPO) is THB 50 million higher than
that of providing palliative care in
a first year of implementation and
will increase to THB 500 million at
the fifth year
The most cost-effective intervention
for treating chronic hepatitis type
B, lamivudine, has already been
covered under the benefit
package
2. Treatment for people with
chronic hepatitis C
Pegylated interferon alpha 2a (Peg2a) 
ribavirin for treating hepatitis type C
subtype 1, 4, 5, and 6 is the most cost-
effective (ICER  THB 86,600 per QALY)
compared with palliative care and with
other alternatives:
- Interferon alpha  ribavirin, Peg2a 
ribavirin, pegylated interferon alpha 2b
(Peg2b) 1 g/1 kg of body weight 
ribavirin, Peg2b 1.5 g/1 kg of body
weight  ribavirin
Providing Peg2a for treating hepatitis
type C subtype 1, 4, 5, and 6 is
increasing budget by THB 3,500
million. Providing Peg2b for
treating hepatitis type C subtype 3
is increasing budget by THB 8,600
million. Therefore, it would be in
total THB 12,000 million in 5 years
Not recommended because of high
budget impact
3. Treatment for severe lupus
nephritis
Intravenous cyclophosphamide (IVC) 
azathioprine (AZA) for 3 y is the most
cost-effective (cost-saving) compared
with the standard treatment for
treating lupus nephritis (IVC with
decreasing dose for 3 y) and with the
other alternatives (i.e., IVC 
mycophenolate mofetil [MMF] for 3 y,
MMF  AZA for 3 y, MMF with
decreasing dose for 3 y)
Budget of treatment is approximately
THB 1.4–1.5 million per patient
The most cost-effective intervention
for treating lupus nephritis (i.e.,
IVC 1,000 mg/mo for 6 mo and
then AZA 50 mg/d for further
2.5 y) has already been covered
under the benefit package
4. Smoking cessation
program
Every intervention for smoking cessation
is cost-effective (cost-saving) (i.e.,
counseling at the hospital, counseling
by quit line, counseling  nicotine
gum, counseling  nicotine patch,
counseling  bupropion, counseling 
nortriptyline, and counseling 
varenicline) compared with no
intervention (suddenly quit smoking
by themselves; smokers)
In case of providing nortriptyline (as
a first-line drug) 80%  nicotine
gum 10%  varenicline (as a
second-line drug) 10%, the budget
would be THB 273 million in a first
year and would increase to THB
566 million at the fifth year
All interventions for smoking
cessation are cost-effective.
Therefore, the program is
recommended for further
consideration to be adopted in
the benefit package
5. Anti-IgE for severe asthma Omalizumab (anti-IgE) is not cost-
effective (ICER  THB 414,503 per
QALY) compared with standard clinical
practice guideline (steroid) for severe
asthma
Providing omalizumab to treat
patients with severe asthma
increases the budget by THB 54,000
million per year and will increase
the budget by THB 270,000 million
in 5 y
Not recommended because it is not
a cost-effective intervention and
the budget estimation per year is
very high
6. Implant dentures for
people who have problem
with conventional
complete dentures
Implant dentures is cost-effective (ICER 
THB 5,147 per QALY)
The 5-y budget will be THB 280–781
million on the basis of expected
target population and will be THB
83–208 million on the basis of
human resource (health
professionals) capacity
Not recommended because
problems of access to standard
treatment of dental care were still
unsolved
7. Absorbent products for
urinary and fecal
incontinence among
disabled and elderly
people
Absorbent product is cost-effective
(ICER  THB 54,000 per QALY)
Budget of providing absorbent
products to the disabled and
elderly is approximately THB 4,800
million per year
Not recommended because of high
budget impact
8. System for screening,
treatment, and
rehabilitation of
alcoholism
N/A N/A Not recommended because of
inadequate information (in 2010)
9. Screening for risk factors
for leukemia in people
living in the industrial
areas
N/A N/A (the researchers estimated social
costs of illness instead: from the
model of 50,000 populations who
are living in the industrial areas
with migration of 1,000 people per
year, social costs of illness would
be THB 3,500 million in 30 y)
Recommended for further
consideration to be adopted in
the benefit package because the
problem causes considerable loss
in terms of cost of illness at THB
3,500 million in 30 y
GPO, the government pharmaceutical organization; IgE, immunoglobulin E; ICER, incremental cost-effectiveness ratio; N/A, not available; QALY,
quality-adjusted life-year; SLE, systemic lupus erythematosus; THB, Thai baht.
* In 2010, US $1 was approximately 30.17 baht [26].
act 
968 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 6 1 – 9 7 0Discussion
This research and development project, initiated by the NHSO in
Thailand, is a first attempt to achieve rational, transparent, and
fair health care rationing through the application of MCDA in a
real-world context. MCDA was applied in the various steps
throughout the project to identify (selection and assessment) cri-
teria, to construct performance matrixes, and to elaborate on
these before coming to final conclusions. Although it is difficult to
judge in the absence of quantified standards, MCDA seems to have
considerably contributed to fairness in priority setting. Themerits
of MCDA are especially clear when the present process is com-
pared with the situation before where priority setting was said to
be ad hoc and driven by interests of stakeholder groups.
Deliberation is an important component of MCDA. Whereas
the performance matrix quantifies the performance of interven-
tions on selected criteria, the consideration of other criteria (that
cannot be quantified or were for other reasons missing in the per-
formancematrix) is vital inMCDAand is captured in the process of
deliberation. As an example, the intervention “absorbent products
for urinary and fecal incontinence among disabled and elderly
people” was selected for assessment, even though its score was
not in the top rank. In the present project, criteria such as “vulner-
ability,” “a more cost-effective alternative,” and “feasibility of im-
plementation”were put forward in the deliberation process in step
2 (selection of interventions for assessment).
This article described only the first year of experience of the
use of MCDA to develop the UC benefit package and did not cap-
ture the final coverage decisions. The SCBP is now consulting with
the Tobacco Research and Knowledge Management Center in
Thailand to make the “smoking cessation program” part of the
tobacco prevention program. Likewise, the SCBP is now consulting
with NHSO’s Department of Health Promotion and Disease Pre-
vention to incorporate the screening program for leukemia in its
regular work. Both interventions still need further consideration
before they can be covered under the UC scheme. As to the “ab-
sorbent products for urinary and fecal incontinence among dis-
abled and elderly people,” initially the SCBP members seemed to
support the coverage of this intervention on ethical aspects, that
is, the clear need for this intervention when the assessment was
Table 4 – The relationship between assessment and appra
Policy
recommendation
Cost-effective
(ICER 1 per-capita GDP/QA
Low budget impact† High
Recommended ● Lamivudine for treatment of
people with chronic hepatitis B
● Intravenous cyclophosphamide 
azathioprine for treating severe
lupus nephritis
● Smoking cessation program
Not recommended ● Implant dentures for people who
have problem with conventional
complete dentures
● Pegylate
 ribav
hepatiti
● Absorbe
urinary
incontin
and eld
ICER, incremental cost-effectiveness ratio; GDP, gross domestic prod
* Two cost analysis studies, that is, screening for risk factors for leu
treatment, and rehabilitation of alcoholism, are not included in thi
† High budget impact THB 200 million per annum; low budget impongoing in 2010. This intervention was finally denied by the SCBPfor inclusion because of its large budget impact (SCBP meeting in
July 2011).
Our study has a number of limitations. First, the scoring scales
of some criteria were difficult to define, such as targeting the poor
and those with rare diseases. A clear definition of both terminol-
ogies was lacking; therefore, in this project, the definition and
scoring scales development were determined on the basis of ex-
perts’ opinion and the international guideline that is, World
Health Report 2002 [21]. Although these two information sources
are acceptable, country-specific and more reliable evidence for
creating the criteria’s and the scoring scales’ definition should be
developed. Second, we found a lack of comparable evidence of
each intervention on the severity of disease criterion. Because it
would be costly and time-consuming to conduct an empirical
study for all proposed interventions, only partial information and
expert opinion on this criterionwere considered.While severity of
disease has been widely used in priority setting to balance be-
tween equity and efficiency in many settings [30–32], this limita-
tion has led to a doubt in using this criterion in MCDA. Hence, this
flags serious attention for its further measurement. Third, some
criteria, such as effectiveness, were difficult to understand for
nonacademic people—this constituted a barrier to achieving con-
sensus in group discussions as laypeople were dominated by
higher educated people. The project however did not consider this
reason to delay involving the public in the process of priority set-
ting and informed all stakeholders as much as possible on the
way. Fourth, all criteria used in this project were determined to
carry equal weights, which may not reflect the local values in re-
ality. Although the relative weights of criteria analyzed from the
discrete choice experiments were considered by the research
team and the SCBP, they were not used directly—weighing of cri-
teria may be considered in future projects. Then, the question
should also be addressed how the potentially divergent weights
from the various stakeholders can be accommodated. Fifth, the
framework of A4R was purposively selected to evaluate the prior-
itization process of the project. There are, however, other evalua-
tion tools that can be applied for assessing the resource allocation
process such as a framework of internal and external parameters
for evaluating successful priority setting in low- and middle-in-
come countries [33] and a checklist for assessing nine common
esults.
essment results*
Not cost-effective
(ICER 1 per-capita GDP/QALY)
et impact† Low budget impact High budget impact
— — —
rferon alpha 2a
r treating
oducts for
ecal
among disabled
eople
— ● Anti-immunoglobulin E
for severe asthma
ALY, quality-adjusted life-year; THB, Thai baht.
a in people living in the industrial areas, and system for screening,
le.
THB 200 million per year.isal r
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LY)
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s C
nt pr
and f
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erly p
uct; Q
kemi
s tabthemes of good practice for health research priority setting [34].
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process, and some interventions’ performance on some criteria
used for example, severity of disease, effectiveness of interven-
tions, or economic impact of household expenditure, is likely to
change over time. For example, changing population structure can
lead to an increase or decrease in some disease incidence, or the
availability of a new intervention can lead to a change in the costs
of an existing intervention. This can be drawn from the case of
“pegylate interferon alpha 2a and ribavirin for treating hepatitis C”
that was not recommended at the initial decisionmaking because
of its high budgetary impact. At the end of 2011, however, this
combined intervention for treating hepatitis C was eventually in-
cluded in the benefit package because the lower price of the inter-
vention, due to extensive price negotiation between the Thai Min-
istry of Public Health and pharmaceutical companies, resulted in a
lower budget impact. Hence, priority setting of interventions is a
continuous process. It means that some interventions that failed
to be prioritized in the first place may need to be reconsidered
again in the future because they may become priorities then. Onincluded in the benefit package can become obsolete and should
be delisted from the package.
Although the present project has applied MCDA in the Thai
context,MCDA—as a general approach—is applicable or adaptable
to other settings. This would require identification of priority-set-
ting criteria as relevant to that setting, including assigningweights
and/or scores for each criterion, and the assessment of perfor-
mance of all interventions on these criteria, to arrive at a context-
specific priority-setting process. That would then not only in Thai-
land but also in other settings lead to decisions that are more
rational, transparent, and fair. This was, however, not a compar-
ative project; hence it cannot lead to conclusions whether the
MCDA approach would have led to better decisions with regard to
the allocation of resources to health interventions. Rather, it de-
scribes the practice of MCDA and presents its values as can be
evaluated by using the A4R framework.
Source of financial support: The first author was supported by
the World Health Organization under its Fellowship Program to
study at Radboud University Nijmegen Medical Centre, The Neth-the other hand, it is possible that some interventions previously erlands.
Appendix 1 Scores of the proposed health interventions against the selection criteria
Health interventions Selection criteria
Size of
population
affected by
disease
Severity
of
disease*
Effectiveness
of health
intervention
Variation
in
practice
Economic
impact on
household
expenditure
Equity/ethical
and social
implication
Total
1. Anti-immunoglobulin E for severe
asthma
4 — 3 5 5 1 18
2. Treatment for people with chronic
hepatitis B
5 — 4 2 3 3 17
3. System for screening, treatment,
and rehabilitation of alcoholism
5 — 5 4 1 1 16
4. Implant dentures for people who
have problem with conventional
complete dentures
5 — 2 2 5 1 15
5. Screening for risk factors for
leukemia in people living in the
industrial areas
4 — 3 5 1 2 15
6. Treatment for severe lupus
nephritis
2 — 4 2 5 1 14
7. Smoking cessation program 5 — 3 2 1 3 14
8. Treatment for people with chronic
hepatitis C
3 — 5 2 3 1 14
9. Absorbent products for urinary
and fecal incontinence among
disabled and elderly people
4 — 2 2 4 1 13
10. Treatment for unfertilized women 5 — 0 2 5 1 13
11. Renal replacement by dialysis for
new final stage renal failure
patients
2 — 1 5 4 1 13
12. Screening and treatment for liver
cancer
2 — 3 2 5 1 13
13. Physical examination package
(following the Civil Servant
Medical Benefit Scheme)
5 — 0 5 1 1 12
14. Cissus quadrangularis L. for
hemorrhoid
5 — 1 4 1 1 12
15. Biological agents for psoriasis 1 — 1 2 5 2 11
16. Screening for gall bladder cancer 2 — 2 2 1 3 10
17. Orbital implant and plastic
surgery of orbit and facial bones
1 — 2 1 1 2 7
* Severity of disease was omitted from the criteria list in the first year of the project (2010).
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